Clinitech laboratory has filed its quarterly disclosure under SEBI Regulation 74(5) of the Depositories and Participants Regulations, 2018 for the quarter ended March 31, 2026. The disclosure, submitted to BSE Limited on April 07, 2026, confirms the company's compliance with dematerialisation requirements.

Quarterly Demat Status Report

The company's Registrar and Transfer Agent, Bigshare Services Pvt. Ltd., confirmed that SEBI Regulation 74(5) is not applicable to Clinitech Laboratory Limited during the quarter ended March 31, 2026. This exemption applies because the entire shareholding of the company remains in dematerialised form.

Regulatory Compliance Framework

The disclosure was signed by Chairman and Managing Director Jagdish Umakant Nayak on behalf of the company and submitted with proper digital authentication. The certificate from Bigshare Services Pvt. Ltd. was dated April 06, 2026, and subsequently forwarded to BSE Limited on April 07, 2026.

Previous Compliance Activities

This filing follows the company's earlier submission of its annual disclosure under SEBI Regulation 31(4) for FY26, which was filed on April 06, 2026. The previous disclosure confirmed that no encumbrance was made over shares held by promoters and persons acting in concert during the financial year.

Documentation Details

The quarterly disclosure includes confirmation from the company's RTA that no shareholders requested conversion of their dematerialised shares back to physical form during the reporting period. This status maintains the company's full compliance with modern securities trading requirements, where all shares remain in electronic format for efficient trading and settlement.

Clinitech Laboratory has announced the acquisition of 9,600 equity shares by promoter Jagdish Umakant Nayak through an open market transaction completed on March 30, 2026. This represents the latest in a series of acquisitions by the promoter group, following recent purchases by other promoter group members.

Latest Transaction Details

The share purchase by Jagdish Umakant Nayak, who serves as Promoter & Managing Director, represents the largest single acquisition in the recent series of promoter group investments. The transaction was executed through open market operations and disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Updated Shareholding Pattern

Following this latest acquisition, the promoter group's collective shareholding has increased significantly. The transaction reflects the continued commitment of the promoter group to strengthen their stake in the diagnostic services company.

Recent Promoter Group Activity

This acquisition follows a series of recent transactions by promoter group members, including purchases by Siddhesh Anant Nayak (2,400 shares on March 27, 2026) and an earlier acquisition by Jagdish Umakant Nayak (1,200 shares on March 25, 2026). The combined transactions demonstrate sustained investment by the promoter group.

Promoter Group Structure

The disclosure identifies the complete promoter group structure with Jagdish Umakant Nayak as the primary promoter. The promoter group includes several persons acting in concert (PACs):

• Jagdish Umakant Nayak (Promoter & Managing Director)
• Jyoti Jagdish Nayak
• Ashutosh Jagdish Nayak
• Ananya Jagdish Nayak
• Anant Umakant Nayak
• Siddhesh Anant Nayak
• Eshwari Anant Nayak

Regulatory Compliance

The transaction was properly disclosed to the Bombay Stock Exchange Limited (BSE), where Clinitech Laboratory Limited shares are listed under scrip code 544220. The disclosure fulfills the company's obligations under SEBI regulations for substantial acquisition reporting. The acquired shares carry full voting rights and represent equity participation in the diagnostic laboratory services provider.